loading
전일 마감가:
$13.50
열려 있는:
$13.52
하루 거래량:
382.31K
Relative Volume:
0.37
시가총액:
$903.08M
수익:
-
순이익/손실:
$-119.67M
주가수익비율:
-4.8901
EPS:
-2.73
순현금흐름:
$-97.30M
1주 성능:
+9.52%
1개월 성능:
-6.12%
6개월 성능:
-3.82%
1년 성능:
+11.25%
1일 변동 폭
Value
$12.90
$13.87
1주일 범위
Value
$11.77
$14.83
52주 변동 폭
Value
$8.241
$18.38

Mineralys Therapeutics Inc Stock (MLYS) Company Profile

Name
명칭
Mineralys Therapeutics Inc
Name
전화
(888) 378-6240
Name
주소
150 N. RADNOR CHESTER ROAD, RADNOR
Name
직원
51
Name
트위터
Name
다음 수익 날짜
2024-11-12
Name
최신 SEC 제출 서류
Name
MLYS's Discussions on Twitter

MLYS을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
MLYS
Mineralys Therapeutics Inc
13.35 903.08M 0 -119.67M -97.30M -2.73
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
489.10 127.47B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.16 62.43B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
596.20 37.03B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
234.56 31.06B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
230.98 26.16B 3.81B -644.79M -669.77M -6.24

Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2024-07-10 개시 H.C. Wainwright Buy
2024-04-02 개시 Goldman Buy
2023-03-07 개시 BofA Securities Buy
2023-03-07 개시 Credit Suisse Outperform
2023-03-07 개시 Evercore ISI Outperform
2023-03-07 개시 Guggenheim Buy
2023-03-07 개시 Stifel Buy
2023-03-07 개시 Wells Fargo Overweight
모두보기

Mineralys Therapeutics Inc 주식(MLYS)의 최신 뉴스

pulisher
Apr 18, 2025

Mineralys, Tenaya, SpringWorks, COSCIENS, Metagenomi: 5 Biotech Stocks That Led Retail Follower Growth Last Week - MSN

Apr 18, 2025
pulisher
Apr 16, 2025

Mineralys therapeutics CEO Jon Congleton sells shares worth $186,802 By Investing.com - Investing.com Canada

Apr 16, 2025
pulisher
Apr 15, 2025

Mineralys Therapeutics CFO Adam Levy sells $129,684 in stock - Investing.com Australia

Apr 15, 2025
pulisher
Apr 15, 2025

Mineralys Therapeutics chief medical officer sells $165,185 in stock - Investing.com Australia

Apr 15, 2025
pulisher
Apr 15, 2025

Mineralys Therapeutics CFO Adam Levy sells $129,684 in stock By Investing.com - Investing.com India

Apr 15, 2025
pulisher
Apr 15, 2025

Mineralys Therapeutics Executives Sell Shares - TradingView

Apr 15, 2025
pulisher
Apr 15, 2025

Mineralys therapeutics CEO Jon Congleton sells shares worth $186,802 - Investing.com

Apr 15, 2025
pulisher
Apr 12, 2025

Institutional investors must be pleased after a 8.1% gain last week that adds to Mineralys Therapeutics, Inc.'s (NASDAQ:MLYS) one-year returns - Yahoo Finance

Apr 12, 2025
pulisher
Apr 09, 2025

SEC Form DEF 14A filed by Mineralys Therapeutics Inc. - Quantisnow

Apr 09, 2025
pulisher
Apr 09, 2025

SEC Form DEFA14A filed by Mineralys Therapeutics Inc. - Quantisnow

Apr 09, 2025
pulisher
Apr 07, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 07, 2025
pulisher
Apr 03, 2025

Mineralys Therapeutics CMO Rodman sells shares worth $879,008 - Investing.com Australia

Apr 03, 2025
pulisher
Apr 03, 2025

Mineralys Therapeutics CMO Rodman sells shares worth $879,008 By Investing.com - Investing.com Canada

Apr 03, 2025
pulisher
Apr 02, 2025

Buy Rating Affirmed for Lorundrostat Amid Positive Trial Results and Market Potential - TipRanks

Apr 02, 2025
pulisher
Apr 01, 2025

When (MLYS) Moves Investors should Listen - news.stocktradersdaily.com

Apr 01, 2025
pulisher
Apr 01, 2025

Stifel maintains Buy on Mineralys stock with $45 target - Investing.com Australia

Apr 01, 2025
pulisher
Apr 01, 2025

ACC25: Mineralys' uncontrolled hypertension drug aces trial - Pharmaphorum

Apr 01, 2025
pulisher
Mar 31, 2025

Stifel maintains Buy on Mineralys stock with $45 target By Investing.com - Investing.com South Africa

Mar 31, 2025
pulisher
Mar 31, 2025

Mineralys Therapeutics Unveils Promising Trial Results for Lorundrostat - TipRanks

Mar 31, 2025
pulisher
Mar 30, 2025

Mineralys Therapeutics presents results from Phase 2 Advance-HTN trial - TipRanks

Mar 30, 2025
pulisher
Mar 30, 2025

Promising Clinical Trial Results and Safety Profile of Lorundrostat Support Buy Rating for Mineralys Therapeutics - TipRanks

Mar 30, 2025
pulisher
Mar 30, 2025

Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology's Annual Scientific Session & Expo (ACC.25) - The Manila Times

Mar 30, 2025
pulisher
Mar 29, 2025

Mineralys Therapeutics Announces Late-Breaking Data from - GlobeNewswire

Mar 29, 2025
pulisher
Mar 29, 2025

Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology’s Annual Scientific Session & Expo (ACC.25) - TradingView

Mar 29, 2025
pulisher
Mar 29, 2025

Breakthrough Hypertension Drug Achieves 15.4 mmHg Blood Pressure Drop in Critical Phase 2 Trial - Stock Titan

Mar 29, 2025
pulisher
Mar 28, 2025

Mineralys Therapeutics, Inc. Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology's Annual Scientific Session & Expo (ACC.25) - Marketscreener.com

Mar 28, 2025
pulisher
Mar 27, 2025

Mineralys Therapeutics to Host Webinar on Lorundsrostat and Hypertension Treatment Progress - MSN

Mar 27, 2025
pulisher
Mar 26, 2025

3 Brilliant Space Stocks to Buy Now and Hold for the Long Term - The Globe and Mail

Mar 26, 2025
pulisher
Mar 26, 2025

Insiders Make Huge Purchases of These 4 Biotech Stocks - 24/7 Wall St.

Mar 26, 2025
pulisher
Mar 25, 2025

Mineralys Therapeutics, Inc. (MLYS): Among Stocks Receiving the Most Insider Love in March - Insider Monkey

Mar 25, 2025
pulisher
Mar 25, 2025

Mineralys Therapeutics to Host KOL Call to Discuss Clinical - GlobeNewswire

Mar 25, 2025
pulisher
Mar 25, 2025

Mineralys Therapeutics to Host Conference Call on Advance-HTN and Launch-HTN Clinical Trial Results Featuring Dr. Luke Laffin - Nasdaq

Mar 25, 2025
pulisher
Mar 25, 2025

Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET - The Manila Times

Mar 25, 2025
pulisher
Mar 25, 2025

Groundbreaking Hypertension Treatment Data: Cleveland Clinic Expert Reveals Pivotal Trial Results - Stock Titan

Mar 25, 2025
pulisher
Mar 24, 2025

MLYS Stock Price and Chart — NASDAQ:MLYS - TradingView

Mar 24, 2025
pulisher
Mar 21, 2025

RA CAPITAL MANAGEMENT, L.P. Increases Stake in Mineralys Therape - GuruFocus

Mar 21, 2025
pulisher
Mar 20, 2025

Lorundrostat Shows Promise in Treatment of Uncontrolled and Resistant Hypertension in trials - Medical Dialogues

Mar 20, 2025
pulisher
Mar 20, 2025

Buy Rating Justified for Mineralys Therapeutics, Inc. Due to Promising Study Results and Manageable Safety Profile - TipRanks

Mar 20, 2025
pulisher
Mar 19, 2025

Mineralys Therapeutics to Present Phase 2 Advance-HTN Trial Data at ACC.25 - MSN

Mar 19, 2025
pulisher
Mar 19, 2025

Mineralys Therapeutics Announces Closing of Underwriters' Option to Purchase Additional Shares in Connection with Public Offering of Common Stock - The Manila Times

Mar 19, 2025
pulisher
Mar 18, 2025

Is Mineralys Therapeutics, Inc. (MLYS) a Pump and Dump Stock Favored by Hedge Funds? - Insider Monkey

Mar 18, 2025
pulisher
Mar 18, 2025

Mineralys Therapeutics Announces Closing of Underwriters’ - GlobeNewswire

Mar 18, 2025
pulisher
Mar 18, 2025

Mineralys Therapeutics Announces Closing of Underwriters’ Option to Purchase Additional Shares in Connection with Public Offering of Common Stock - Marketscreener.com

Mar 18, 2025
pulisher
Mar 18, 2025

Mineralys Therapeutics Raises Massive $201M as Investors Back Promising Drug Development - StockTitan

Mar 18, 2025
pulisher
Mar 18, 2025

10 Pump and Dump Stocks Favored by Hedge Funds - Insider Monkey

Mar 18, 2025

Mineralys Therapeutics Inc (MLYS) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

Mineralys Therapeutics Inc 주식 (MLYS) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Rodman David Malcom
Chief Medical Officer
Apr 14 '25
Sale
14.53
11,366
165,185
111,686
Levy Adam Scott
CFO and Secretary
Apr 11 '25
Sale
12.06
10,757
129,684
215,340
Congleton Jon
Chief Executive Officer
Apr 11 '25
Sale
12.19
15,319
186,803
862,289
$20.04
price up icon 2.51%
$72.65
price up icon 3.49%
$32.60
price up icon 1.27%
$24.61
price up icon 6.77%
$98.76
price up icon 0.52%
biotechnology ONC
$230.98
price up icon 1.24%
자본화:     |  볼륨(24시간):